How I Treat Ph+ Acute Lymphoblastic Leukemia: Controversial Treatment Options


The treatment of Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia has significantly changed with the advent of tyrosine kinase inhibitor (TKI) therapy. This talk will review: (1) choice of TKI therapy in the upfront setting; (2) the role of allogeneic hematopoietic stem cell transplant in CR1; and (3) novel approaches being evaluated in the “frail” patient.


  • Anjali Advani


Member Type Price
List Price $30.00
Active, International, Emeritus, and Honorary Members $20.00
Associate, International Associate, Student, and Resident Members $20.00
back to top